ADANI POWER: WINS 1,234 MW LONG-TERM THERMAL POWER SUPPLY CONTRACT FROM UTTARAKHAND FOR 25 YEARS

QATAR MINISTER: STIFLING REGULATIONS, HIGH TAXES ARE HINDRANCES

NAVKAR CORPORATION LIMITED: CO. RECEIVES LETTER OF ACCEPTANCE FOR CONSTRUCTION & OPERATION OF GATI SHAKTI MULTI-MODAL CARGO TERMINAL; CONTRACT VALUED AT APPROX. ₹48 CRORE;

RAILTEL CORP: CO WINS ORDER WORTH RUPEES 197 CR

AEROFLEX INDUSTRIES: APPROVES CAPACITY ENHANCEMENTS AND EXPANSION PLANS; SS HOSE & BRAIDING DIVISION TO INCREASE CAPACITY TO 30 MILLION METERS; LIQUID COOLING SFN SKID ASSEMBLIES TO REACH 30,000 PIECES; TOTAL INVESTMENT ESTIMATED AT ₹202 CRORES.

UPDATE ON INSURANCE COMMISION SECTOR IRDAI UNLIKELY TO EXTEND OR GIVE RELEIF TO REFORMS NORMS: ET NOW

UPDATE ON INSURANCE COMMISION SECTOR IRDAI UNLIKELY TO EXTEND OR GIVE RELEIF TO REFORMS NORMS: ET NOW (PB FINTECH, TURTLEMINT FINTECH)

INDIA (SEP) WHOLESALE PRICE YOY ACTUAL: 11.39% VS 9.92% PREVIOUS;EST 10.60%

AHLUWALIA CONTRACTS: CO WINS ORDER WORTH RUPEES 310 CR

BHEL: Q2 SL NET PROFIT 8.1B RUPEES VS 3.68B (YOY); EST 6.54B

BHEL: Q2 EBITDA 10B RUPEES VS 5.8B (YOY), EST 8.81B; Q2 EBITDA MARGIN 11.03% VS 7.73% (YOY), EST 9.5%

BHEL: Q2 REVENUE 93B RUPEES VS 75.12B (YOY); EST 92.36B

GROWW: Q2 CONS NET PROFIT 7.3B RUPEES VS 4.7B (YOY); EST 6.8B

GROWW: Q2 EBITDA 9.68B RUPEES VS 6.04B (YOY); Q2 EBITDA MARGIN 64.44% (YOY)

GROWW: Q2 REVENUE 15B RUPEES VS 10.2B (YOY)

Trump says amnesty for illegal immigrants will "never happen"

DIESEL SUPPLIES TO REMAIN CONSTRAINED WELL INTO 2027, IEA WARNS

IEA: SEES 2027 WORLD OIL SUPPLY 3.94M BPD ABOVE DEMAND (PREV FORECAST 3.73M BPD ABOVE); RESTRICTED MIDDLE DISTILLATE SUPPLY TO PERSIST WELL INTO 2027 AS DIESEL MARKETS UNDER SIGNIFICANT STRAIN FROM PROLONGED DISRUPTIONS

ELECON ENGINEERING — Q2 RESULTS

Net Profit: ₹96.35 Cr ↑10% YoY | ↑37% QoQ

Revenue: ₹638.94 Cr ↑11% YoY | ↑23% QoQ

EBITDA: ₹147.90 Cr ↑18% YoY | ↑38% QoQ

EBITDA Margin: 23.1% vs 21.7% YoY | 20.6% QoQ

BHEL — Q2 FY27 RESULTS

Net Profit: ₹809.62 Cr ↑120% YoY | ↑112% QoQ

Revenue: ₹9,300.35 Cr ↑24% YoY | ↑21% QoQ

EBITDA: ₹1,025.80 Cr ↑77% YoY | ↑104% QoQ

EBITDA Margin: 11.0% vs 7.7% YoY | 6.5% QoQ

BHEL — Q2 FY27 RESULTS VS ESTIMATES

Net Profit: ₹810 Cr vs ₹654.4 Cr estimated — Beat by 23.8%

Revenue: ₹9,300 Cr vs ₹9,236 Cr estimated — Beat by 0.7%

EBITDA Margin: 1% vs 0.5% estimated — Beat by 50 bps

Apollo Hospital, Max Healthcare and Hospital In Focus – Big Negative; Big Margin Cut Could Come

Central Government Affidavit Says
Average markup on non-scheduled cancer drugs stands at 170%

Some anti-cancer drugs have markups of 700% or more

Allegations of drug retail margins exceeding 1,800% were put to committee

Govt says anti-cancer drug market is worth about 12,500 cr/year

Market for non-scheduled cancer drugs with no price cap is 10,000 cr/year

Consumable margins of 100% to more than 1,000% are prevalent in hospitals

Healthcare consumers have limited ability to compare prices before treatment

Patients often cannot substitute medicines prescribed during hospital treatment

Cancer patients operate with little bargaining power in treatment decisions

NPPA duty extends beyond monitoring prices to preventing profiteering

Canara Bank - TV interview- Guidance up

- See Credit growth in H2 better than earlier guidance

- Expects improvement in net interest margins ahead